+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Market Spotlight: Neuropathic Pain

  • ID: 4421386
  • Report
  • 40 pages
  • Datamonitor Healthcare
1 of 2
This Market Spotlight report covers the neuropathic pain market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, upcoming events, probability of success, patent information, a 10-year disease prevalence forecast, and licensing and asset acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways:
  • The author estimates that in 2017, there were 425.2 million prevalent cases of neuropathic pain in adults aged 20 years and older worldwide, and forecasts that number to increase to 476.2 million prevalent cases by 2026.
  • Asia is estimated to have had the largest number of prevalent cases in 2017, driven by population size, while having the lowest prevalence proportion (98.1 million cases; 3.2%).
  • The marketed drugs in the neuropathic pain space target sodium channels, voltage-gated calcium channels, and transient receptor potential vanilloid receptor 1. These drugs are administered via the oral route, except for Qutenza, which is available as a topical formulation.
  • The majority of industry-sponsored drugs in active clinical development for neuropathic pain are in Phase I. Therapies in development for neuropathic pain focus on a wide variety of targets. The majority of pipeline drugs in early- and mid-stage development are administered orally, with the remainder being intravenous, intramuscular, intraarticular, intrathecal, intradermal, subcutaneous, and topical formulations.
  • High-impact upcoming events for drugs in the neuropathic pain space comprise topline Phase II trial results for AP-325 and Dysport.
  • The overall likelihood of approval of a Phase I neuropathic pain asset is 0.9%, and the average probability a drug advances from Phase III is 33.3%. Drugs, on average, take 8.9 years from Phase I to approval, compared to 9.7 years in the overall neurology space.
  • There have been 28 licensing and asset acquisition deals involving neuropathic pain drugs during 2014–19, eight of which occurred in 2015. The exclusive licensing agreement in 2015 between Depomed and Janssen for the acquisition of the US rights to Nucynta for $1.05bn was the largest deal.
  • The distribution of clinical trials across Phase I–IV indicates that the majority of trials have been in the early and mid-phases of development, with 69% of trials in Phase I–II, and only 31% in Phase III–IV.
  • The US has a substantial lead in the number of neuropathic pain clinical trials globally. The UK leads the major EU markets, while Japan has the top spot in Asia.
  • Clinical trial activity in the neuropathic pain space is dominated by completed trials. Pfizer has the highest number of completed clinical trials for neuropathic pain, with 230 trials.
  • Pfizer leads industry sponsors with by far the highest number of clinical trials for neuropathic pain, followed by Allergan
Note: Product cover images may vary from those shown
2 of 2
OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND
  • Subtypes
TREATMENT
  • Antidepressants
  • Antiepileptics
  • Cannabinoids
  • Opioids
  • Topical or focal therapies
EPIDEMIOLOGY
  • Limitations of neuropathic pain prevalence estimates
MARKETED DRUGS

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION
  • VX-150 for Neuropathic Pain (December 18, 2018)
KEY UPCOMING EVENTS

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS
  • Eli Lilly licenses exclusive rights to develop and sell CNTX0290 from Centrexion
PARENT PATENTS

REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE
  • Sponsors by status
  • Sponsors by phase
  • Recent events
BIBLIOGRAPHY
  • Prescription information
APPENDIX

LIST OF FIGURES
Figure 1: Trends in prevalent cases of neuropathic pain, 2017–26
Figure 2: Overview of pipeline drugs for neuropathic pain in the US
Figure 3: Pipeline drugs for neuropathic pain, by company
Figure 4: Pipeline drugs for neuropathic pain, by drug type
Figure 5: Pipeline drugs for neuropathic pain, by drug classification
Figure 6: VX-150 for Neuropathic Pain (December 18, 2018): Phase II - Small Fiber Neuropathy
Figure 7: Key upcoming events in neuropathic pain
Figure 8: Probability of success in the neuropathic pain pipeline
Figure 9: Licensing and asset acquisition deals in neuropathic pain, 2014–19
Figure 10: Parent patents in neuropathic pain
Figure 11: Clinical trials in neuropathic pain
Figure 12: Top 10 drugs for clinical trials in neuropathic pain
Figure 13: Top 10 companies for clinical trials in neuropathic pain
Figure 14: Trial locations in neuropathic pain
Figure 15: Neuropathic pain trials status
Figure 16: Neuropathic pain trials sponsors, by phase

LIST OF TABLES
Table 1: Prevalence methodology
Table 2: Prevalent cases of neuropathic pain, 2017–26
Table 3: Prevalence proportions of neuropathic pain, 2017–26
Table 4: Marketed drugs for neuropathic pain
Table 5: Pipeline drugs for neuropathic pain in the US
Table 6: VX-150 for Neuropathic Pain (December 18, 2018)
Table 7: Historical global sales, by drug ($m), 2014–18
Table 8: Forecasted global sales, by drug ($m), 2019–23
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll